|
|
|
|
| LEADER |
00632nam a22002171a 4500 |
| 003 |
AR-BaBNM |
| 005 |
20251014092655.0 |
| 007 |
ta |
| 008 |
130830s1990 fr 000 0 |||||||||spa d |
| 020 |
|
|
|a 92-832-1531-1
|
| 035 |
|
|
|a 000162405
|
| 040 |
|
|
|a AR-BaBNM
|b spa
|e aacr
|
| 080 |
|
|
|a 616-006.6
|
| 245 |
0 |
0 |
|a Pharmaceutical drugs.
|
| 260 |
|
|
|a Lyon :
|b IARC,
|c 1990.
|
| 300 |
|
|
|a 415 p.
|
| 490 |
0 |
|
|a IARC Monographs on the evaluation of the cancinogenic risk of humans ;
|v 50
|
| 650 |
|
4 |
|a Neoplasmas
|9 6873
|
| 710 |
1 |
|
|a World Health Organization
|b International Agency for research on cancer
|
| 942 |
|
|
|2 udc
|c LIBRO
|n 1
|
| 999 |
|
|
|c 155257
|d 155257
|